Aromasin

Aromasin

exemestane

Manufacturer:

Pfizer

Distributor:

DKSH

Marketer:

DKSH
Concise Prescribing Info
Contents
Exemestane
Indications/Uses
Adjuvant treatment of post-menopausal women w/ estrogen receptor +ve early breast cancer who have received 2-3 yr tamoxifen & switched to Aromasin for completion of a total of 5 consecutive yr adjuvant hormonal therapy. Advanced breast cancer in women w/ natural or induced postmenopausal status whose disease has progressed following anti-estrogen therapy alone. Postmenopausal woman whose disease has progressed following multiple hormonal therapies.
Dosage/Direction for Use
Administration
Should be taken with food.
Contraindications
Hypersensitivity. Women of childbearing potential. Pregnancy.
Special Precautions
Anticipated bone mineral density reductions. Monitor for osteoporosis; risk factors for osteoporosis. Perform routine assessment of 25-hydroxy vit D levels prior to treatment. Not to be co-administered w/ estrogen-containing medicines. May affect ability to drive & use machines. Not to be administered to women w/ premenopausal endocrine status. Not to be used during lactation.
Adverse Reactions
Depression, insomnia; headache, dizziness; hot flushes; abdominal pain, nausea; increased hepatic enzyme, blood bilirubin & alkaline phosphatase; increased sweating; joint & musculoskeletal pain; pain, fatigue. Anorexia; carpal tunnel syndrome, paraesthesia; vomiting, diarrhea, constipation, dyspepsia; alopecia, rash, urticaria, pruritus; fracture, osteoporosis; peripheral oedema.
MIMS Class
Cancer Hormone Therapy
ATC Classification
L02BG06 - exemestane ; Belongs to the class of enzyme inhibitors. Used in treatment of neoplastic diseases.
Presentation/Packing
Form
Aromasin tab 25 mg
Packing/Price
30's
Register or sign in to continue
Asia's one-stop resource for medical news, clinical reference and education
Sign up for free
Already a member? Sign in